SCNI
Scinai Immunotherapeutics Ltd (SCNI)
Healthcare • NASDAQ • $0.57+3.65%
- Symbol
- SCNI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.57
- Daily Change
- +3.65%
- Market Cap
- $2.01M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $6.18
- 52W Low
- $0.46
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 2.19
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of Na…
Company websiteResearch SCNI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.